Skip to content

Study · Not a test of the peptide alone · 1993

4 results

Tissue concentrations of prothymosin alpha: a novel proliferation index of primary breast cancer.

Dominguez F, Magdalena C, Cancio E, Roson E, Paredes J, Loidi L, Zalvide J, Fraga M, Forteza J, Regueiro BJ

European journal of cancer (Oxford, England : 1990)1 Jan 1993Cited by 45 (Europe PMC)

PMID8387320 (opens in a new tab)DOI10.1016/s0959-8049(05)80433-2 (opens in a new tab)PepBankPUB-08387320
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

  1. 01HumanNot a test of Thymosin alpha-1 aloneObservational studyOther

    In 71 patients with invasive ductal carcinoma, prothymosin alpha levels measured with a thymosin alpha‑1 assay were greater in tumour than in normal breast tissue.

    In plain wordsIn breast cancer patients, prothymosin alpha (measured with a thymosin alpha‑1 test) was higher in tumour tissue than in normal breast tissue.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseProthymosin alpha level, tumour versus normal tissue
    Study

    n = 71

    human breast tumour and normal breast tissue
    Comparator
    Normal breast tissue
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    In 71 patients with classic invasive ductal carcinomas, levels of prothymosin alpha (PT alpha), as assayed by a radioimmunoassay that detects thymosin alpha 1 (the NH2-terminal fragment of PT alpha), were significantly greater in tumour samples than in normal breast tissue.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  2. 02HumanNot a test of Thymosin alpha-1 aloneObservational studyOther

    All 21 patients who developed distant metastases had tumour prothymosin alpha levels above 124 ng thymosin alpha‑1 per mg protein.

    In plain wordsAll 21 breast cancer patients whose cancer spread had high prothymosin alpha levels in their tumour.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableTumour prothymosin alpha level in patients with distant metastases
    Study

    n = 21

    human breast tumour and normal breast tissue
    Outcome group
    Tumor growth · Cancer

    Measurements

    Tumour prothymosin alpha level
    > 124 ng thymosin alpha 1/mg protein
    patients with distant metastases

    Source sentences

    Summary
    Since the beginning of this study in 1989, 21 patients have presented distant metastases, all of whom were previously shown to have tumour PT alpha levels greater than 124 ng of thymosin alpha 1/mg protein.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  3. 03HumanNot a test of Thymosin alpha-1 aloneObservational studyOther

    Prothymosin alpha levels correlated with the number of positive axillary lymph nodes.

    In plain wordsHigher prothymosin alpha levels in breast tumours were linked to more cancer-positive lymph nodes.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableProthymosin alpha level and positive axillary lymph nodes
    Study

    n: not reported in source

    human breast tumour and normal breast tissue
    Outcome group
    Tumor growth · Cancer

    Measurements

    Spearman correlation coefficient (rs)
    0.5384 coefficient
    positive axillary lymph nodes

    Source sentences

    Summary
    PT alpha levels were correlated with (a) the number of positive axillary lymph nodes (rs = 0.5384, P < 0.01)

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  4. 04HumanNot a test of Thymosin alpha-1 aloneObservational studyOther

    Prothymosin alpha levels correlated with the percentage of tumour cells in the S or G2/M phase.

    In plain wordsHigher prothymosin alpha levels in breast tumours were linked to more tumour cells that were dividing.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableProthymosin alpha level and S or G2/M phase tumour cells
    Study

    n: not reported in source

    human breast tumour and normal breast tissue
    Outcome group
    Tumor growth · Cancer

    Measurements

    Spearman correlation coefficient (rs)
    0.5027 coefficient
    tumour cells in S or G2/M phase

    Source sentences

    Summary
    (b) the percentage of tumour cells in the S or G2/M phase as assessed by flow cytometry (rs = 0.5027, P < 0.01).

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.